Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676386 · ClinicalTrials.gov registry record
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Terminated
- Registry status
- 29
- Enrollment target
NCT04676386: Clinical Trial study, sponsored by Addario Lung Cancer Medical Institute.
NCT04676386 is a clinical trial that was terminated before completion, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04676386 was terminated before completion, sponsored by Addario Lung Cancer Medical Institute.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) \> 50% and ECOG performance status (PS) 0-2 NSCLC patients who are treated with PD-1/PD-L1 based therapy with or without the addition of platinum based chemotherapy.
Primary Outcome
To collect biospecimens and evaluate candidate biomarkers of early progression on patients with \>50% PD-L1 positive tumors treated with PD-1/PD-L1 monotherapy or PD-1/PD-L1/chemotherapy combination
Interventions
- DIAGNOSTIC_TEST Primary Immune Response (PIR) test by Biodesix, Inc.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-12-30 |
Why NCT04676386 stopped before completion
NCT04676386 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Primary Immune Response (PIR) test by Biodesix, Inc. is the first listed.
NCT04676386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04676386 about?
NCT04676386 is a clinical study titled "Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy". This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) \> 50% and ECOG performance status (PS) 0-2 NSCLC patients who are treated with PD-1/PD-L1 ...
What is the current status of trial NCT04676386?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2021-02-01. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04676386?
The interventions under investigation include: Primary Immune Response (PIR) test by Biodesix, Inc. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04676386?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI